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Abstract 
Background: The genetics of depression has been explored in genome-wide association studies that 
focused on major depressive disorder or depressive symptoms with mostly negative findings. A 
broad depression phenotype including both phenotypes has not been tested previously using a 
genome-wide association approach. We aimed to identify genetic polymorphisms significantly 
associated with a broad phenotype from depressive symptoms to major depressive disorder. 
Methods: We analysed two prior studies of 70,017 participants of European ancestry from general 
and clinical populations in the discovery stage. We performed a replication meta-analysis of 28,328 
participants. SNP-based heritability and genetic correlations were calculated using LD score 
regression. Discovery and replication analyses were performed using a P-value based meta-analysis. 
Lifetime major depressive disorder and depressive symptom scores were used as the outcome 
measures.  
Results: The SNP-based heritability of major depressive disorder was 0.21 (SE=0.02), the SNP-based 
heritability of depressive symptoms was 0.04 (SE=0.01), and their genetic correlation was 1.001 
(SE=0.2). We found one genome-wide significant locus related to the broad depression phenotype 
(rs9825823, chromosome 3: 61,082,153, P=8.2x10-9) located in an intron of the FHIT gene. We 
replicated this SNP in independent samples (P= 0.02) and the overall meta analysis of the discovery 
and replication cohorts (1.0x10-9). 
Conclusions: This large study identified a new locus for depression. Our results support a continuum 
between depressive symptoms and major depressive disorder. A phenotypically more inclusive 
approach may help achieve the large sample sizes needed to detect susceptibility loci for depression.   
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Introduction 
The etiology of depression – a worldwide leading cause of disability (1) – is not well understood. As 
indicated by family, twin and adoption studies, genetic factors mediate part of vulnerability to major 
depressive disorder (MDD) with a modest heritability of around 40% (2). However, we understand 
little of the specific genetic architecture of MDD. Multiple genome-wide association studies (GWAS) 
for MDD have been published (3-10). The largest MDD GWAS was the mega-analysis by the MDD 
Working Group of the Psychiatric Genomics Consortium (PGC). In that study, over 9,000 MDD cases 
and 9,500 controls were analyzed but no association with MDD reached genome wide significance 
(7). Recently, CONVERGE (China, Oxford and VCU Experimental Research on Genetic Epidemiology) 
consortium identified two genome-wide significant associations in 5,303 Chinese women with severe 
and recurrent MDD (near the SIRT1 gene, P=2.53x10-10 and in an intron of the LHPP gene, P=6.45x10-
12) (11).  A GWAS of depressive symptoms (heritability 23%-29%) (12, 13) in the Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) consortium in approximately 50,000 people from 
the general population found no genome-wide significant associations (14). Due to the relatively 
small sample sizes, the previous GWAS of depressive disorders and depressive symptoms were 
arguably underpowered to detect small genetic effects (15, 16).  
Depression can be conceptualized along a continuum of severity from subthreshold or minor 
depression to MDD of varying severity (e.g., mild, moderate, and severe) (17). Using a continuum 
approach may augment statistical power as sample size can be increased substantially and patients 
who fall into the ‘grey area’ can be assessed. Several lines of evidence support a depression 
continuum. In longitudinal studies, there is an increased risk of MDD in patients with minor 
depression and subthreshold depression (18, 19). Statistical studies of disorder classification 
(taxometric) suggested that severity of depression is continuously distributed and there is no 
discontinuity in the latent structure of depression (19, 20). Family studies report that relatives of 
probands with milder forms of depression have greater risk of MDD compared to relatives of 
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probands without any mood disorders (21-24). A higher number of depressive symptoms is related 
to greater disability, worse quality of life, and a higher mortality risk (18, 25-29). MDD and 
continuous measures of depression are highly correlated and severity of depressive symptoms along 
the continuum is linear (30, 31). 
The goal of the current study was to combine the results of the largest GWAS using categorical 
lifetime MDD and continuous measures of depression to identify genetic variants underlying the 
entire depression continuum. 
Methods and Materials 
Study Design and Samples 
This study was a collaboration between investigators on the PGC MDD and CHARGE genome-wide 
association meta-analyses (GWAMA). In the discovery phase, we aggregated two GWAMA published 
in 2013 (7, 14). Basic descriptive features and phenotype definitions of the contributing samples are 
provided in eTable 1. The mega-analysis of MDD consisted of nine studies of 9,240 cases meeting 
international criteria for lifetime MDD and 9,519 healthy controls. The CHARGE meta-analysis of 
depressive symptoms included 22 cohorts and comprised 51,258 persons. Each cohort contributing 
to the GWAMA of the PGC and CHARGE were distinct. In the replication analyses, 16 case-control 
studies with DSM-IV MDD (6,718 cases and 13,453 controls) were included along with 8,157 subjects 
from the general population with assessment of depressive symptoms. All subjects were of European 
ancestry. Institutional review boards approved all studies and all participants provided written 
informed consent.  
Phenotype Characteristics 
In the PGC GWAMA, MDD was established with structured clinical interviews (e.g., Clinical Interview 
Schedule-Revised, Diagnostic Interview for Genetic Studies, and the Structured Clinical Interview for 
DSM-IV). All clinical evaluations were made by experienced clinicians/interviewers. Most cases were 
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ascertained from clinical sources. Controls were screened in most of the studies to require the 
absence of MDD and recruited from the general population. Full details about the PGC samples can 
be found in the previous publication (7). In the CHARGE GWAMA, depressive symptoms were 
assessed with validated questionnaires. Measures include the Center for Epidemiological Studies-
Depression (CES-D) scale, Geriatric Depression Scale (GDS), Patient Health Questionnaire-9, and the 
Beck Depression Inventory-II (BDI-II) mostly assessing depressive symptoms in previous weeks rather 
than lifetime MDD (14). Persons with schizophrenia, bipolar disorder, and dementia were excluded. 
Persons aged 40 and older and with genotype data and depressive symptom score were included. 
The 16 MDD case-control replication samples were part of an expanded but unpublished PGC MDD 
analysis. MDD was diagnosed with interviews. In the depressive symptom replication cohort, the 
Health and Retirement Study, the 8-item CESD was applied. Respondents were excluded if they were 
less than 40 years of age or evidence of cognitive impairment. 
Genotyping and Imputation 
In the PGC samples, (eTable 1), individual genotypes were assembled, processed through a central 
quality control pipeline and imputed using the CEU and TSI HapMap3 reference panels. Quality 
control procedures were extensive (7). In the CHARGE cohorts, genotype quality control and 
imputation were conducted in each study separately. The imputation reference was the HapMap2 
Central EUrope (CEU) panel (14). In the MDD replication cohorts (eTable 3), imputation was 
performed using IMPUTE2 / SHAPEIT (chunk size of 3 Mb and default parameters). The imputation 
reference set consisted of 2,186 phased haplotypes from the 1000 Genomes Project. In the Health 
and Retirement Study, imputation was performed using the HapMap2 CEU reference panel.  
Statistical Analyses 
LD score regression was used to compute the SNP-based heritability and the genetic correlation 
using the 1000 Genomes CEU  reference panel (32).  
Direk N, Page 11 of 22 
In the PGC GWAMA, a logistic regression analysis was used to test the association between MDD and 
imputed SNP dosages under an additive model and adjusting for study indicators and five principal 
components (7). In the CHARGE GWAMA, a linear regression analysis was applied to test the 
association of depressive symptom score on imputed SNP dosages in the contributing studies 
adjusting for age and sex. Analyses were adjusted for principal components for most but not all 
cohorts in the CHARGE GWAMA. A P value based meta-analysis was applied in the CHARGE GWAMA 
(14). Effect size estimates were based on a dichotomous outcome in the PGC and on a continuous 
outcome in the CHARGE GWAMA. To combine these effect estimates, a P value based meta-analysis 
weighted by sample size with METAL was used. This method allows different weights for each study 
and takes into account the direction of effect at each SNP (33). To specify the direction of the effect, 
the PGC used the logistic regression coefficient beta and the CHARGE used z-scores. Weights were 
based on the number of the MDD cases in the PGC study (n=9,240) and the number of individuals in 
the CHARGE with clinically significant depressive symptoms (n=5,976) using population specific cut-
off scores of the questionnaires were considered for weighting. To test whether the results are 
affected by different sample size weightings, equal weights per study, or no weight as suggested by 
Stouffer (34), we carried out a series of sensitivity analyses.  
We selected the genome wide significant SNPs in two loci from the discovery stage for replication. 
After analyzing these data, we performed a P value based meta-analysis combining all replication 
samples. Further, we analyzed the results of the discovery and all replication samples weighting for 
number of cases.  
Results 
In the discovery stage, we performed a GWAMA in 70,017 participants of European ancestry by 
combining the PGC MDD (7) and CHARGE GWAMA (14). We applied an LD score regression to the 
summary statistics from each study to compute the SNP-based heritabilities and the genetic 
correlation. As reported previously (35), the SNP-based liability scale heritability of MDD was 0.2 
Direk N, Page 12 of 22 
(standard error 0.02) for 20% of prevalence. The lambda was 1.1 and the regression intercept was 
1.0 (standard error 0.01). The SNP-based heritability of depressive symptoms was 0.04 (standard 
error 0.01). The lambda was 1.1 and the regression intercept was 1.0 (standard error 0.01). The SNP-
based heritability of the broad depression phenotype was 0.3 (standard error 0.04). MDD and 
depressive symptoms showed significant co-heritability (1.001, standard error 0.2, Z-score= 4.6, 
P=4.6x10-6). This result supports the contention of a continuum between depressive symptoms and 
MDD. However, the genetic correlation should be interpreted carefully as LD regression is quite 
sensitive to environmental confounding and like twin studies often lacks precision. Also, different 
evaluation methods of the depression phenotypes might cause different genetic correlation 
estimates that cannot easily be compared. 
We conducted a meta-analysis of the PGC MDD and the CHARGE depressive symptoms GWAMA 
using a weighted, P-value based meta-analysis. The results are summarized in Figure 1 and eFigures 
1-3. The combined meta-analysis was conducted for 918,921 SNPs. Two loci were genome-wide 
significant: a SNP in an intron of FHIT (rs9825823, chr3: 61,082,153, P =8.2x10-9) and a SNP in an 
intron of PLEK2 (rs9323497, chr14: 67,873,128, P=3.3x10-8) (Table 1). All SNPs with a P value of 
association <5x10-5 are presented in eTable 2. Using different weights or Stouffer’s unweighted 
method had only slight effects on the results (data not shown). eFigure 4 and 5 shows forest plots for 
two SNPs shown in Table 1.  
Table 2 presents the replication analyses and the meta-analysis of discovery and replication results. 
One of the genome-wide significant variants within the FHIT gene (rs9825823) was associated with 
depression continuum in the replication cohorts (z-score=2.4, P=0.02). The result of the final meta-
analysis of discovery and replication samples also indicated a positive replication as indexed by a 
lower p-value (z-score=6.1, P=1.0x10-9). This SNP had a positive association with depressive 
symptoms in the CHARGE study (P=5.5 x 10-4) and a similar pattern was observed in the PGC study 
(P=4.1 x 10-6). The SNP in an intron of PLEK2 (rs9323497) was not related to depression continuum 
significantly (z-score=0.2, P=0.9). 
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We performed an additional replication analysis of our two genome-wide significant SNPs using the 
publicly available data of the recently published GWAMA of depressive disorders in a sample of 
Chinese women (the CONVERGE study) (11). In CONVERGE, rs9825823 (odds ratio=1.01, P=0.12) and 
rs9323497 (odds ratio=0.97, P=0.0002, with a different direction of association than in our discovery 
sample) were not related to depression at the genome-wide significance level although the latter 
reached nominal significance. However, in the joint meta-analysis of the HRS, PGC MDD and the 
CONVERGE studies, we found that the association between the rs9825823 and the depression 
continuum (z-score=2.85, P=0.004) was slightly stronger than our initial replication analysis. When 
these replication and discovery samples were combined, the association with our top hit also 
became stronger (analyses without the CONVERGE data: z-score= 6.1, P = 1x10-9; with the CONVERGE 
data z-score= 6.2, P = 6.8x10-10). Results of additional replication analyses are given in the eTable 4.  
Discussion 
We report the results of a combined GWAMA of depression continuum including MDD (18,759 cases 
and controls) and depressive symptoms (51,258 participants). In the discovery stage, we found 
genome-wide significant associations in the FHIT and PLEK2 genes. One SNP in the intron of the FHIT 
gene showed a significant association in the combined analysis of discovery and replication samples 
of MDD and depressive symptoms samples, and exceeded a genome-wide significance threshold .  
The significant locus (rs9825823, chr3: 61,082,153) maps to the intronic region of the fragile histidine 
triad (FHIT) gene, a tumor suppressor protein implicated in several cancers (36). FHIT is expressed in 
multiple brain regions (amygdala, anterior cingulate cortex, caudate nucleus, prefrontal cortex, 
hippocampus, and hypothalamus, http://www.gtexportal.org/home/gene/FHIT, accessed 
10.07.2016). It plays an important role in oxidative stress and level of DNA damage (37), biological 
processes implicated in MDD (38, 39). FHIT is a circadian clock modifier gene (40) and has been 
related to daytime sleepiness (41), which may be salient to the etiology of depression.  
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In a GWAS of recurrent, early-onset MDD, three SNPs located in the FHIT gene were among the 
strongest associations in the overall and sex-stratified analyses (8) although none was genome-wide 
significant. Genetic variants located in FHIT have been reported in genetic studies of anxiety,(42) 
autism (43), mental stress (44), comorbid depressive syndromes and alcohol dependence (45), 
citalopram-induced side effects (46) and in a latent class analysis of MDD symptoms (7), but none 
met genome-wide significance.  
Several methodological aspects should be discussed. First, we evaluated depression continuum by 
combining cases from clinical populations diagnosed with MDD and participants from the general 
population who had been assessed for depressive symptoms. Such an inclusive approach may 
increase heterogeneity of the phenotype especially because lifetime MDD was evaluated whereas 
depressive symptoms indicate past weeks only. If anything, such approach would cause an 
underestimation of the effects as less information on depressive symptoms were obtained. However, 
the advantages of a large sample can outweigh the disadvantages of a less precisely defined 
phenotype. This has been observed in the GWAS of educational attainment which was successfully 
used as a proxy for intelligence (47). Our additional replication analysis showed that increasing the 
sample size yielded a stronger association of the top hit with depression continuum. It is complex to 
calculate statistical power of the current analysis as quantitative and qualitative measures were 
combined. In the current study, a genetic association with the depression continuum may reflect an 
effect on broad depressive phenotypes but could also be accounted for by an association with low 
levels of general well-being (12-18% heritability) that co-occur with depressive symptoms (48). 
Second, we used a P-value based meta-analysis, as effect estimates could not be directly evaluated in 
a straightforward manner. Third, the heterogeneity of the imputation methods used in the PGC and 
CHARGE discovery samples might reduce the statistical power. However, different imputation 
references did not change the results in the published PGC MDD study (7).  
Direk N, Page 15 of 22 
In conclusion, in this large GWAMA of a broad depression phenotype, we detected a locus associated 
with depression in clinical and general population samples. Our results suggest the importance a 
broader depression phenotype to identify genetic variants underlying depression. Large samples with 
different depression phenotypes may also help disentangle the genetic background of different 
forms of depression. 
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Figure legends 
Figure 1: Manhattan Plot  
X-axis represents the chromosomal position for each SNP, and y-axis the -log10 P value for 
association with depression.  
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Table 1. Meta-analysis results of the PGC MDD GWAMA and the CHARGE depressive symptoms GWAMA(discovery)  
      Combined meta-analysis* (Ntotal=70,017) 
SNP Chr BP Closest Gene Location Allele MAF Direction z-score P 
rs9825823 3 61,082,153 FHIT intron T/C 0.46 ++ 5.8 8.2x10-9 
rs9323497 14 67,873,128 PLEK2 intron T/C 0.05 ++ 5.5 3.3x10-8 
Chr: chromosome, BP: base pair, MAF: minor allele frequency (GRCh37/hg19). Allele: Minor/Major on the + strand. Direction of effect: CHARGE 
(N=51,258; continuous outcome analysis), PGC (N=18,759; of which 9,240 were MDD cases). * This analysis was weighted for number of participants 
with clinically significant depressive symptoms in the CHARGE study (n=5,976) and number of cases in the PGC study (n=9,240).  
 
 
Table 2. Replication analyses and final meta-analysis of discovery and replication stages 
   
PGC replication 
(N=20,171) 
 
HRS replication 
(N= 8,157) 
 
Overall replication 
(N=28,328) 
 
Meta-analysis of discovery & two 
replication samples (N= 98,345) 
SNP Chr:BP Allele Direct.a P  Direct. P  Direct.b P  MAF Direct.c z-score P 
rs9825823 3:61,082,153 T/C +++--++-+-++--++ 0.04 + 0.2 ++ 0.02  0.46 +++ 6.10 1.0x10-9 
rs9323497  14:67,873,128 T/C +-+----++++---++ 0.8 - 0.8 +- 0.9  0.05 -++ 4.61 4.0x10-6 
Chr: Chromosome, BP: base pair, MAF: minor allele frequency (GRCh37/hg19), Direct=Direction. Allele: Minor/Major on the + strand. a Order of the studies: The Cognitive Function and 
Mood Study (CoFaMS), The PsyCoLaus Study, MDD2000-Edinburgh, GENPOD/NewMeds, Depression Genes Networks, GenRED2, Harvard i2b2, Janssen, The Marx Planck Institute of 
Psychiatry (MPIP) Munich Antidepressant Response Signature (MARS) Study OMNIex, QIMR COEX, Radiant Irish, Radiant US Cases, Radiant Denmark Cases, Roche, SHIP Trend, TwinGene. b 
Order of the studies: PGC- replication Health and Retirement Study. c Order of the studies: PGC- replication, Health and Retirement Study, combined meta-analysis of discovery samples.  
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